eprintid: 10078071 rev_number: 20 eprint_status: archive userid: 608 dir: disk0/10/07/80/71 datestamp: 2019-07-16 10:03:32 lastmod: 2021-11-15 03:32:18 status_changed: 2019-07-16 10:03:32 type: article metadata_visibility: show creators_name: D'Haens, G creators_name: Rieder, F creators_name: Feagan, BG creators_name: Higgins, PDR creators_name: Panes, J creators_name: Maaser, C creators_name: Rogler, G creators_name: Löwenberg, M creators_name: van der Voort, R creators_name: Pinzani, M creators_name: Peyrin-Biroulet, L creators_name: Danese, S creators_name: IOIBD Fibrosis Working Group, . title: Challenges in the Pathophysiology, Diagnosis and Management of Intestinal Fibrosis in Inflammatory Bowel Disease ispublished: inpress divisions: UCL divisions: B02 divisions: C10 divisions: D17 divisions: G91 note: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. abstract: Intestinal fibrosis is a common complication of inflammatory bowel disease (IBD) that is usually the consequence of chronic inflammation. Although the currently available anti-inflammatory therapies have had little impact on intestinal fibrosis in Crohn’s disease (CD), increased understanding of the pathophysiology and the development of therapies targeting fibrogenic pathways hold promise for the future. One of the critical challenges is how reduction or reversal of intestinal fibrosis should be defined and measured in the setting of clinical trials and drug approval. The International Organization for Inflammatory Bowel Disease (IOIBD) organized a workshop in Amsterdam, The Netherlands, on December 19th and 20th, 2018 in an attempt to review the current knowledge of the biological background, diagnosis, treatment of intestinal fibrosis and clinical trial endpoints. Basic and clinical scientists discussed the pathophysiology of intestinal fibrosis, the current status of biomarkers and imaging modalities in stenosing CD, and recent clinical studies in this area. Researchers from outside of the IBD field presented advances in the understanding of fibrotic processes in other organs, such as the skin, liver and lungs. Lastly, the design of clinical trials with antifibrotic therapy for IBD was discussed, with priority on patient populations, patient reported outcomes (PROs) and imaging. This report summarizes the key findings, discussions and conclusions of the workshop. date: 2019-06-27 date_type: published official_url: https://doi.org/10.1053/j.gastro.2019.05.072 oa_status: green full_text_type: other language: eng primo: open primo_central: open_green article_type_text: Journal Article verified: verified_manual elements_id: 1672593 doi: 10.1053/j.gastro.2019.05.072 pii: S0016-5085(19)41035-4 language_elements: English lyricists_name: Pinzani, Massimo lyricists_id: MPINZ74 actors_name: Flynn, Bernadette actors_id: BFFLY94 actors_role: owner full_text_status: public publication: Gastroenterology event_location: United States issn: 0016-5085 citation: D'Haens, G; Rieder, F; Feagan, BG; Higgins, PDR; Panes, J; Maaser, C; Rogler, G; ... IOIBD Fibrosis Working Group, .; + view all <#> D'Haens, G; Rieder, F; Feagan, BG; Higgins, PDR; Panes, J; Maaser, C; Rogler, G; Löwenberg, M; van der Voort, R; Pinzani, M; Peyrin-Biroulet, L; Danese, S; IOIBD Fibrosis Working Group, .; - view fewer <#> (2019) Challenges in the Pathophysiology, Diagnosis and Management of Intestinal Fibrosis in Inflammatory Bowel Disease. Gastroenterology 10.1053/j.gastro.2019.05.072 <https://doi.org/10.1053/j.gastro.2019.05.072>. (In press). Green open access document_url: https://discovery.ucl.ac.uk/id/eprint/10078071/7/Pinzani_Challenges%20in%20the%20Pathophysiology%2C%20Diagnosis%20and%20Management%20of%20Intestinal%20Fibrosis%20in%20Inflammatory%20Bowel%20Disease_AAM.pdf